We have recently studied the influence of HLA class I allele-level mismatches in a well-defined population of transplant patients (n ¼ 171). 1 We could not detect any adverse effect of HLA-A, -B, or -C allele mismatches on overall survival (Figure 1 ) or on other clinical end points, for early as well as advanced disease stages.
1 Our findings are different from those of Flomenberg et al.
2 This retrospective study of 1874 unrelated donor marrow transplants facilitated by the NMDP suggested that allelelevel class I mismatches affected outcome adversely. The NMDP study is 10-fold larger than ours, raising the question of whether our search and selection strategiesguided so far by our own experience -should be revised.
The NMDP study population 2 was heterogeneous with respect to sex, age, race, center, time of treatment, graft manipulation, and other variables. While the general approach to dealing with these confounding variables was described in the paper, specific details of the analysis were not available. This makes it difficult to compare the major findings of this study with previous studies. Additionally, the statistical approach in the study to select confounding variables 2 is not universally accepted.
3
Whether a given HLA mismatch has an impact on transplant outcome or not depends upon the specific clinical context, including the conditioning regimen, stem cell source, GVHD prophylaxis, graft manipulation, etc. Thus, even the best attempts to correct for a myriad of possible clinical confounders using advanced statistical techniques may result in conclusions that are erratic or erroneous. HLA-DQB1 may serve as an example. The NMDP study 2 would imply that HLA-DQB1 should no longer be considered a transplantation antigen. However, the only reason for this is that no effect could be identified by means of tests for statistical differences after adjustment for all possible confounders including HLA mismatches at other loci. 4 We believe that the role of HLA-A, -B, and -C allele mismatches in HSCT can only be clarified with prospective studies in homogeneous, precisely defined clinical settings. Retrospective data, whether they are from registries 2 or single centers, 1 can only be considered suggestive.
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